Our mission is to introduce an innovative, high-quality drug-delivery technology to improve fat grafting technique and impact women's health and quality of life.
Sebana Medical innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented SEBA™ proprietary platform. The SEBA™ is and advanced Biologic Slow-Release Technology made from biodegradable PLGA-Matrix Microparticles Polymer which is an ideal carrier for the pharmaceutical active ingredient (API). The API is a safe natural biologic and an approved molecule by the FDA which the company has shown it safety and efficacy in preventing fat cell death.
SEBA™, our flagship product is indicated for treating fat grafts in breast reconstruction following mastectomy. Sebana Medical ambition is to clinical prove the efficacy and commercialize SEBA™ for breast reconstruction and plastic surgery markets by 2025.
Sebana Medical will start testing the product in clinical breast reconstruction trials in 2022. The breakthrough innovation that Sebana Medical has developed was made possible by combining different skillsets in advanced drug slow-release polymer technology, science and pharmaceutical development.
Sebana Medical's Team is ambitious to introduce the first pharmaceutical product that prevents fat resorption in soft tissue augmentation by fat grafting. In addition to our flagship product, SEBA™ can be tailored in several innovative pipeline of products utilizing the SEBA™ technology to prevent fat resorption in fat grafting indications such as wrinkle removal, breast augmentation, buttock augmentation, hand rejuvenation, penile enlargement, and in facial asymmetry.
Breast cancer is the most common cancer in women with lifetime risk of estimated at 1 in 8 women globally. In more than 50%, Mastectomy is the usual treatment, followed by chemotherapy or radiotherapy.
Breast reconstruction is required to restore the shape and volume of the breast in post-cancer rehabilitation. Reconstruction procedure offered are silicone implants by surgery and non-surgical autologous fat tissue grafting. These methods are limited due to repeated procedures and costs for healthcare system, limiting the availability for patients.
Global Risk for Developing Breast Cancer
Women Diagnosed Every Year Globally
Undergo a Mastectomy to Save Their Lives
Need Breast Reconstruction
Up to 80% of the reinjected fat is resorbed and disappears as quickly as within 2 months from the grafting procedure. The plastic surgeons are required to perform repeated fat grafting procedures with autologous fat to obtain the desired results. The accelerated fat resorption is the “Achille’s Heel” of the fat grafting technique for being widely used in breast reconstruction and in soft tissue augmentation.
AUTOLOGOUS FAT TRANSFER
Also called autologous fat grafting. Fat tissue is removed from other parts of the body by liposuction, fat is then processed into liquid and reinjected back into the desired area of the body for soft tissue augmentation. Fat grafting is emerging as a safe and preferred technique to restore the shape and volume of the breast.
SEBA™ innovation is a unique proprietary biologic delivery technology based on biodegradable PLGA-Matrix Microparticles into which EPO substance is embedded. It is possible to administer SEBA™ onto any quantity of fat tissue and control the release of EPO precisely at any desired rate, safely and cost-effectively to prevent fat resorption after a fat grafting procedure.
Chief Operational Officer
VP Business Affairs
Ola Baker, Sebana’s Business Director with a demonstrated history of working in the pharmaceuticals industry. Skilled in Business Management, Pharmaceutics, Business Planning and, Oncology. Mrs. Baker is a strong business professional with a Bachelor’s degree focused in biology and MBA degree from Haifa University.
VP Marekting & Medical Affairs
Rogette Hinnawi, Sebana’s VP Marketing & Medical affairs, has well over a decade of experience in Marketing, Pharmaceutical Analysis and Medical Management in the pharmaceutical industries around the globe. Mrs. Hinnawi holds a M.Sc. in Information Design and Marketing.
Head Of Pharmaceutics
& Regulatory Affairs
Muhamad Safadi, Sebana’s Head of Pharmaceutics and Regulatory Affairs has more than 25 years of a demonstrated success in pharmaceutical development. Dr. Safadi holds a Ph.D. in Chemistry from Hebrew University, Jerusalem Israel. He oversees the R&D activities and the Regulatory/QA activities in Sebana.
Jenny Firger, Sebana’s Product Biomaterial Designer. She has more than 10 years of a demonstrated success in biodegradable biologic slow-release products and pharmaceutical development.
Suher Masri, Sebana’s C.M.C Manager, has more than 15 years of a demonstrated success in pharmaceutical formulations. Mrs. Masri holds a M.Sc. from Bar-Ilan University, Tel Aviv, Israel. In Sebana she manages the Chemical, Manufacturing and Control activities of SEBA development.
BOARD OF DIRECTORS
Saher Hamed, MD, PhD, Chairman
Founder & Managing Director, Remedor Biomed; Co-founder ADEMEX Life Science. Saher Hamed is a successful innovator and biopharmaceutical expert whose background combines deep business, scientific and medical knowledge with broad scientific, industry, entrepreneurial, and investment experience. He serves on the boards of several biotechnology companies and serves non-profit boards. Dr. Hamed holds an M.D from Nice University and Ph.D from the Technion-Israel Institute of Technology.
Amal Ayoub, PhD, CEO
Amal Ayoub, Sebana’s CEO, is an experienced executive with over 15 years’ experience in the medical device & pharmaceutical industries specializing in the management of innovative start-ups, strategy, commercialization, business development, and financing. Dr. Ayoub holds a Ph.D. from Ben Gurion University, Beersheba, Israel.
Luc Teot, MD
Luc Teot is head of the Reconstructive Surgery Unit of the Montpellier University Hospital in France. He is an editorial board member of 8 journals and former president of the European Tissue Repair Society. He teaches as professor at the universities of Montpellier, Nantes, Limoges, Antilles and La Réunion. His passion for skin regeneration, reconstruction and scarring.
Noaz Bar-Nir, MBA
Mr. Bar-Nir served for the Chief Executive Officer for Clalit Health Services “Clalit Health Fund” which is the largest and oldest health organization in Israel. The organization provides its services to over 50% of the residents of the State of Israel. Noaz serves as director in numerous respectful companies including ELBIT SYSTEMS Ltd.
Omar Alwan, DMD
Dr. Omar Alwan has over 25 years’ experience in the healthcare industry as an Investor, practitioner, consultant, and business owner. Dr. Alwan has taken part in implementing and executing medical device development projects for managed care organizations and other institutions such as hospitals and provider-based institutions. Dr. Alwan completed his specialty training in Dentistry at the Hebrew University in Jerusalem.
Sadanori Akita, MD
Sadanori Akita is a professor-in-chief of department of plastic surgery, and regeneration of Fukuoka University, Faculty of Medicine. He is expert in clinical research of regenerative tissue enhancement to HIV-drug related-wasting patients and reconstructive surgery with fat grafting.
Yehuda Ullmann, MD
Dr. Yehuda Ullmann is the acting director of the Department of Plastic Surgery at Rambam Health Care Campus. He is also the founder and director of the Aesthetic Plastic Service at Rambam, and is a clinical associate professor of Plastic Surgery, in the Ruth & Bruce Rappaport Faculty of Medicine, of the Technion-Israel Institute of Technology. He specializes primarily in breast reconstruction. His research interests relate mainly to fat injection. He served as Chairman of the Israeli Society of Plastic and Aesthetic Surgery from 2009-11. He is currently Chair of the Physician’s Union at Rambam and Vice-chair of the Israel Employed Physician’s Organization.
Amin Fares, MBA
Mr. Amin Fares is an active Director of Remedor Biomed, a company, specializing in wound healing. Mr. Fares is a recognized investor in life science. He led numerous investments with strategic partnerships in global innovations. Mr. Fares has more than 25 years of senior positions in the innovation sector and medical investments. Amin founded Economic Analysis, an equity fund with one of the biggest financial groups in Israel and led it to a successful investments and exit. Mr. Fares holds BA in economics from the Hebrew University in Jerusalem.
Paul Liu, MD
Paul is Chair and Professor of Plastic Surgery at Brown University. He is chief of plastic surgery at Rhode Island Hospital and a professor of surgery at The Warren Alpert Medical School of Brown University. He most recently served as chief of surgery at Roger Williams Medical Center. He was educated at Harvard Medical School and Oxford University, where he was a Marshall Scholar. Paul is the Co-founder of PAX Therapeutics which is a US-based company commercializing a breakthrough product for tissue regeneration and reconstruction. He has over 30 years of experience in medical and business leadership positions in the women’s healthcare industry.
Finally, a product that is designed to prevent the problem of accelerated fat resorption in breast reconstruction with fat transfer.
Sebana's platform technology excels in simplicity, safety, cost-effectiveness, new and innovative technology.
“Autologous fat grafting after breast reconstruction for mastectomy is done to help improve contour deformities and works really well. The downside is that not all the fat that gets injected lives.”
Stephanie Valente, DO
Director, Breast Surgery, Moll Cancer Center at Fairview Hospital.
“For women who underwent mastectomy for breast cancer, lipofilling is a safe procedure that restores breast volume and shape and that does not increase the risk of recurrent or new breast cancers.”
Steven J. Kronowitz, MD
Huston, Texas, Member of the American Society of Plastic Surgeons (ASPS).
“The survival of fat grafts after injection for breast reconstruction can be quite variable in terms of ultimate survival and retention. However, if the fat graft is accepted, it will be there for life.”
Yehuda Ullmann, MD
Former Chairman of the Israeli Society of Plastic and Aesthetic Surgery.